EPS for Karyopharm Therapeutics Inc. (KPTI) Expected At $-0.58

February 15, 2018 - By Ellis Scott

 EPS for Karyopharm Therapeutics Inc. (KPTI) Expected At $ 0.58
Investors sentiment increased to 2.5 in 2017 Q3. Its up 0.94, from 1.56 in 2017Q2. It increased, as 5 investors sold Karyopharm Therapeutics Inc. shares while 11 reduced holdings. 7 funds opened positions while 33 raised stakes. 27.91 million shares or 3.47% more from 26.98 million shares in 2017Q2 were reported.
4,352 are held by Bnp Paribas Arbitrage Sa. Barclays Pcl has invested 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Swiss National Bank accumulated 56,850 shares. Jpmorgan Chase And holds 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 307,200 shares. 13,895 were accumulated by Price T Rowe Assoc Incorporated Md. Rhumbline Advisers reported 75,207 shares. Legal General Group Public Limited Company invested in 9,318 shares or 0% of the stock. State Street, Massachusetts-based fund reported 556,443 shares. Geode Capital Management Lc owns 265,121 shares for 0% of their portfolio. Blackrock has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 3.04M shares. Citigroup has 1,748 shares for 0% of their portfolio. Sandy Spring Savings Bank invested in 0% or 1,500 shares. Thomas J Herzfeld Advisors Inc has invested 0.02% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Art Advsr Lc invested in 26,552 shares or 0.01% of the stock. Ameritas Investment Prtn Incorporated invested in 2,967 shares.

Since August 29, 2017, it had 0 insider buys, and 17 sales for $1.27 million activity. Shacham Sharon had sold 10,000 shares worth $100,769 on Monday, January 8. $19,500 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares were sold by Mirza Mansoor Raza. Primiano Christopher Brett also sold $18,000 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares.

Analysts expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report $-0.58 EPS on March, 15.They anticipate $0.07 EPS change or 10.77 % from last quarter’s $-0.65 EPS. After having $-0.65 EPS previously, Karyopharm Therapeutics Inc.’s analysts see -10.77 % EPS growth. The stock increased 3.04% or $0.44 during the last trading session, reaching $14.92. About 378,370 shares traded or 84.91% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 21.19% since February 15, 2017 and is uptrending. It has outperformed by 4.49% the S&P500.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Ratings Coverage

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 28 analyst reports since August 11, 2015 according to SRatingsIntel. JP Morgan maintained the shares of KPTI in report on Monday, March 14 with “Overweight” rating. The rating was maintained by Leerink Swann with “Outperform” on Tuesday, August 11. The company was maintained on Tuesday, December 12 by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, August 8 by Canaccord Genuity. JMP Securities maintained the shares of KPTI in report on Wednesday, March 9 with “Market Outperform” rating. The stock has “Buy” rating by H.C. Wainwright on Wednesday, November 15. The company was initiated on Thursday, August 18 by H.C. Wainwright. The firm earned “Buy” rating on Wednesday, September 9 by Jefferies. Jefferies downgraded Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Wednesday, January 6 to “Hold” rating. The stock has “Hold” rating by Jefferies on Tuesday, March 15.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $739.04 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

More important recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: Globenewswire.com which released: “Karyopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment …” on January 25, 2018, also Seekingalpha.com published article titled: “Karyopharm Therapeutics: Buy, Sell, Or Hold?”, Seekingalpha.com published: “What’s Next For Karyopharm Therapeutics?” on December 15, 2017. More interesting news about Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was released by: Globenewswire.com and their article: “Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule …” with publication date: February 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.